New drugs in the US were, on average, approved months before winning approval in the EU, according to new data from The IQVIA ...

Another trial for SIGA Technologies' mpox antiviral has failed, and all enrollment has been stopped, the NIH's National ...

Ace­lyrin is of­fi­cial­ly end­ing de­vel­op­ment of an ex­per­i­men­tal med­i­cine it re­ferred to as a “ di­a­mond in the ...

Companies Beam Therapeutics and Prime Medicines presented research on reducing chemotherapy in gene therapy conditioning, ...

Candel Therapeutics’ viral immunotherapy candidate passed a late-stage test in certain patients with prostate cancer, sending ...

Relay Therapeutics’ stock {$RLAY} rose about 6% on Wednesday morning after it released positive interim data for its PI3Kα ...

Through a new relationship with Eli Lilly, Ro patients can now get easier access to the drugmaker’s discounted, single-dose ...

A survey of 77 biotech executives reveals concerns about FDA changes following Donald Trump's reelection. Martin Makary's ...

Data from a Phase 3 study in second-line breast cancer showed that Eli Lilly’s oral SERD reduced the risk of progression or ...

Moberg Pharma's Terclara fails Phase 3 trial for fungal nail infection maintenance dosing; Bayer exits partnership and ...

Angitia Biopharmaceuticals secured $120 million Series C funding led by Bain Capital Life Sciences. The biotech, founded by ...

Chroma Medicine and Nvelop Therapeutics announced their merger to form nChroma Bio, resulting from a September dinner between ...